7. Natriuretic Peptide Testing in Acute Heart Failure Januzzi et al, AJC 2006 Maisel et al N Engl J Med 2002 Biosite BNP (pg/ml) Roche NT-proBNP Negative Predictive Value >90%
8.
9. Incremental Benefit with Natriuretic Peptide Testing in Acute Heart Failure Muller et al, N Engl J Med 2003 Moe et al, Circulation 2007 IMPROVE-CHF BASEL Biosite BNP (pg/ml) Roche NT-proBNP (pg/ml)
10. Incremental Benefit with Natriuretic Peptide Testing in Acute Heart Failure Muller et al, N Engl J Med 2003 Moe et al, Circulation 2007 IMPROVE-CHF BASEL Biosite BNP (pg/ml) Roche NT-proBNP (pg/ml) HFSA 2010 Guideline Recommendation 4.6: It is recommended that BNP or NT-proBNP levels be assessed in all patients suspected of having HF, especially when the diagnosis is not certain. (Strength of Evidence = A)
11. Risk Stratification: BNP in Acute Heart Failure Logeart et al, J Am Coll Cardiol 2004 Biosite BNP (pg/ml)
12. Risk Stratification: Concordance with Clinical Status Morrow et al, JAMA 2005 Bayer ADVIA BNP (in pg/ml) High BNP at Month 4 Low BNP at Month 4
13.
14.
15.
16. Risk Stratification: Multimarker Strategy (Serial) Miller et al, Circulation 2007 Shionogi BNP (pg/ml)
22. Screening: Echocardiographic Abnormalities (Olmsted County) McKie et al, Hypertension 2006 Roche NT-proBNP (pg/ml) HFSA 2010 Guideline Recommendation 4.3: Routine determination of plasma B-type natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP) concentration as part of a screening evaluation for structural heart disease in asymptomatic patients is not recommended . (Strength of Evidence = B)
23. Prognostic Value of “Screening” Natriuretic Peptides McKie et al, Hypertension 2006 Lowest third <13.4 pg/mL Middle third 13.4–39.7 pg/mL Highest third >39.7 pg/mL Lowest third <36.7 pg/mL Middle third 36.7-109.0 pg/mL Highest third >109.0 pg/mL
24.
25. Linking Biomarkers to Therapy Hare et al, J Am Coll Cardiol 2008 Liggett et al, Nature Med 2008